These press releases are intended for business journalists and analysts/investors
GlaxoSmithKline (GSK) Australia has reported its 2015 results to the Australian Securities and Investment Commission (ASIC) for its pharmaceuticals and vaccines business, as well as GSK Consumer Healthcare (a joint venture with Novartis) and ViiV (a joint venture with Pfizer and Shionogi focused on HIV).
Read more - GSK Australia Reports 2015 results to ASIC Read more
In 2015, GSK Australia made payments totalling $3.6 million to healthcare professionals (HCPs) and health-related organisations (HCOs) for grants, sponsorships and consultancy fees related to chairing and speaking at meetings, assistance with training and participation in advisory boards.
Read more - GSK discloses payments to Australian healthcare professionals in 2015 Read more
GSK advises of a temporary disruption to the supply of Bactroban products
GSK has responded to the state of emergency declared in Fiji by providing funding and urgent supplies of medicine.
Read more - GSK responds to Tropical Cyclone Winston in Fiji Read more
GSK Australia is proud to be partnering with the Australian Government to re-introduce a diphtheria, tetanus, acellular pertussis (DTPa) vaccine on the National Immunisation Program for children at 18-months of age.
New research conducted on behalf of Voltaren and GSK Consumer Healthcare shows that 97 percent of Australians suffer from body aches, with a massive two thirds (68%) experiencing it at least weekly, higher than the other 13 countries included in the survey. Findings show pain impacts our social life, love life, performance at work and ability to parent.
Read more - Australia leads the world in body pain blues Read more
GSK has launched a new immunology research collaboration model – the Immunology Catalyst sabbatical program – designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology.
Australian Professor John Hamilton from the University of Melbourne was the first academic to join the program.
GSK prioritises whooping cough vaccine availability for those most at risk of the disease and confirms uninterrupted supply of Boostrix® to all Australian State, Territory and Federal Government vaccination programs where Boostrix is the vaccine of choice.
GSK is leading the pharmaceutical sector by being first in Australia to introduce a new framework for its medical education program and interactions with healthcare professionals to increase transparency.
Read more - GSK first in Australia with new business model for the pharmaceutical industry Read more
